Corbus Pharmaceuticals Holdings, Inc.

Nasdaq:CRBP

Pharmaceutical Preparations·NORWOOD, MA

Corbus is a surname.

Summary Financials

Revenue

$881,705

-77.6% YoY

FY 2022

Adj. EBITDA

-$48.1M

-5459.1% margin

FY 2025

Net Income

-$40.2M

-4560.4% margin

FY 2025

EPS (Diluted)

-$3.68

FY 2025

Stock Price

$9.41

-1.9%

2026-03-13

52W Range

$4.64 – $20.56

P/E Ratio

-2.6x

Market Cap

$166.9M

Cash

$17.2M

FY 2025

Total Debt

$16.3M

FY 2023

Net Cash

$912,574

FY 2023

Enterprise Value

$166.0M

Debt / EBITDA

0.0x

FY 2022

EV / EBITDA

-3.4x

Employees

—

Revenue

$881,705

-77.6% YoY

FY 2022

Adj. EBITDA

-$48.1M

-5459.1% margin

FY 2025

Net Income

-$40.2M

-4560.4% margin

FY 2025

EPS (Diluted)

-$3.68

FY 2025

Stock Price

$9.41

-1.9%

2026-03-13

52W Range

$4.64 – $20.56

P/E Ratio

-2.6x

Market Cap

$166.9M

Cash

$17.2M

FY 2025

Total Debt

$16.3M

FY 2023

Net Cash

$912,574

FY 2023

Enterprise Value

$166.0M

Debt / EBITDA

0.0x

FY 2022

EV / EBITDA

-3.4x

Employees

—